Nyrada Inc. (NYR.XA)
Cboe AU · AUD
A$0.505 (+4.12%) as of
Key statistics
- 52-week range
- 0.3900 – 1.4350
- Beta
- 1.03
- Revenue (TTM)
- 2.01M
- Profit margin
- 0.00%
- Volume
- 62.42k
About Nyrada Inc.
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.